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Steroids	have	an	 important	 role	 in	growth,	development,	 sexual	differentiation	and	
reproduction.	All	 four	classes	of	steroids,	androgens,	oestrogens,	progestogens	and	
glucocorticoids,	have	varying	effects	on	the	brain.	Androgens	and	oestrogens	are	in-
volved	 in	 the	 sexual	 differentiation	 of	 the	 brain,	 and	 also	 influence	 cognition.	
Progestogens such as progesterone and its metabolites have been shown to be in-
volved	 in	 neuroprotection,	 although	 their	 protective	 effects	 are	 timing-	dependent.	
Glucocorticoids	are	linked	with	stress	and	memory	performance,	also	in	a	dose-	and	
time-	dependent	manner.	Importantly,	dysfunction	in	steroid	function	has	been	impli-
cated	in	the	pathogenesis	of	disease.	Moreover,	regulating	steroid-	signalling	has	been	
suggested as potential therapeutic avenue for the treatment of a number of neurode-
velopmental,	 psychiatric	 and	neurodegenerative	 disorders.	 Therefore,	 clarifying	 the	
role of steroids in typical and atypical brain function is essential for understanding 
typical brain functions, as well as determining their potential use for pharmacological 
intervention in the atypical brain. However, the majority of studies have thus far have 
been conducted using animal models, with limited work using native human tissue or 
cells. Here, we review the effect of steroids in the typical and atypical brain, focusing 
on the cellular, molecular functions of these molecules determined from animal mod-
els, and the therapeutic potential as highlighted by human studies. We further discuss 
the	promise	of	human-	induced	pluripotent	stem	cells,	 including	advantages	of	using	
three-	dimensional	neuronal	cultures	(organoids)	in	high-	throughput	screens,	in	accel-
erating our understanding of the role of steroids in the typical brain, and also with re-
spect to their therapeutic value in the understanding and treatment of the atypical 
brain.
K E Y W O R D S
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neurodevelopmental disorders, oestrogens, psychiatric, schizophrenia, stem cells, synapse, 
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1  | INTRODUCTION
Steroid	 hormones	 are	 cyclical	 chemical	 compounds	 made	 up	 of	
rings of carbon atoms that play an essential role in a wide range 
of physiological functions, including growth, development, en-
ergy metabolism, homeostasis and reproduction. Within the brain, 
these	molecules	exert	profound	effects	on	brain	development,	sex-
ual differentiation, reproductive behaviour and cognition, including 
learning and memory.1-5	 Traditionally,	 steroids	 have	 been	 thought	
to	exert	their	actions	by	binding	to	classic	nuclear	receptors	located	
within cytoplasm, which then translocate to the nucleus and regu-
late	 gene	 transcription	over	 a	 period	of	 hours	 to	 days.	The	 crucial	
structural and functional effects that steroid hormones have on the 
brain have made them prime targets for studying mechanisms as-
sociated	with	gene	 regulation.	For	example,	 a	high	dose	of	 steroid	
hormones where the levels are assumed to be low, and an absence 
where there is supposed to be high levels of a hormone, have trans-
formative effects on the physiology of the brain.2,6 However, it is 
now becoming increasingly apparent that many of the actions that 
steroids	exert	occur	within	a	time	frame	too	rapid	to	be	accounted	
for	by	 this	mode	of	action.	 Indeed,	many	steroid	nuclear	 receptors	
and several novel steroid receptors have been found at the plasma 
membrane, where they are considered to engage with signalling 
proteins.3,4,7,8	 The	 increasing	 appreciation	 of	 the	 contribution	 that	
such	‘membrane-	initiated’	actions	have	on	how	steroids	impact	brain	
function has also led to suggestions that ‘neurosteroids’ may need to 
be regarded more as neuromodulators, or transmitters in addition to 
hormones.9,10	Interestingly,	dysregulation	of	all	four	steroids	classes	
have	been	implicated	in	a	range	of	disorders,	including	stress,	autism-	
spectrum	disorders,	schizophrenia	and	Alzheimer’s	disease,	to	name	
but a few. Moreover, there is continued interest in the use of steroids 
as potential therapeutic agents.1,3,11-14	In	this	review,	we	use	‘atypical	
brain’ to describe abnormal brain development or function that con-
tributes to a specific disorder.
To	date,	much	of	our	understanding	of	the	molecular	and	cellu-
lar	mechanisms	by	which	steroids	exert	their	effects	within	the	brain	
have	originated	from	in	vitro	and	in	vivo	animal	based	models.	Such	
studies have provided a fundamental understanding of the role of 
steroids in neural tissue; however, the effects of these molecules and 
the underlying molecular mechanisms in human neural tissue are not 
well understood. Ethical considerations make working with human 
tissue	a	challenge,	 if	not	 impossible	 in	certain	cases.	Although	sev-
eral	 human	neuroblastoma	 and	 immortalised	neural	 cell	 lines	 exist,	
it could be argued that these cellular systems do not faithfully reca-
pitulate a human neuronal cellular environment of specific neuronal 
linages	or	inherent	differences	that	would	be	expected	between	indi-
viduals.	Thus,	these	cellular	systems	are	not	fully	suited	for	detailed	
cellular and molecular studies investigating the mechanisms under-
lying the effects of steroids in neural cells under typical or atypical 
states. Recent advances in stem cell biology have now provided us 
with the ability to generate native human neurons in which to study 
basic and disease mechanisms.15-18	This	has	led	to	the	ability	to	repro-
gram	patient	somatic	cells	into	human-	induced	pluripotent	stem	cells	
(h-iPSCs)	and	the	subsequent	differentiation	of	these	cells	into	neu-
ral cells of specific lineages.16,17	Importantly,	these	cells	encapsulate	
and recapitulate the genetic landscape and cellular abnormalities as-
sociated	with	complex	disease.19,20 Critically, this approach provides 
a potentially limitless source of live human cells for understanding 
basic neurobiology and disease pathophysiology, as well as for mod-
elling the actions of potential drug targets.16-18,21	This	 review	aims	
to cover the effects of gonadal and adrenal steroids on the brain, in-
cluding	long-	term	effects	on	sexual	differentiation	and	acute	effects	
on cognition and memory. We aim to do this by giving an overview of 
the different physiological effects brought about by steroid hormones 
and then classifying the known nuclear and cytoplasmic mechanisms 
responsible	for	those	effects.	These	topics	have	been	greatly	inves-
tigated and therefore we can only briefly highlight a small selection 
of	studies.	In	addition,	we	discuss	the	effect	of	dysregulated	steroid	
hormone	exposure	and	its	implications	in	atypical	brain	states,	before	
going	on	to	explore	the	possible	use	of	steroid	hormones	as	thera-
peutics.	Finally,	we	discuss	how	the	use	of	human	iPSCs	now	offers	
a novel cellular system in which to better understand the role of ste-
roids in human neurodevelopment, their contribution to disease and 
therapeutic potential.
2  | STEROID HORMONES IN THE TYPICAL 
AND ATYPICAL BRAIN
Although	 sexual	dimorphism	 in	 an	animal	 is	determined	by	biologi-
cal	 sex,	 sexually	 dimorphic	 behaviour	 is	 not	 a	 binary	 phenomenon.	
It	 is	 achieved	 through	 a	 complex	 cascade	of	 cellular	 and	molecular	
changes induced by changing levels of steroid hormones in the cir-
culation.	 Steroid	 hormones	 act	 through	 nuclear	 receptor-	mediated	
mechanisms	 that	 cause	permanent	 sexual	dimorphism	of	 the	brain.	
However, recent studies have shown that, under certain conditions, 
steroid hormones also interact with cell surface receptors to cause 
fast-	acting,	acute	alterations	in	brain	function.	Here,	we	will	discuss	
the	well-	characterised	effects	of	steroid	hormones	on	sexual	dimor-
phism of the brain and the underlying molecular mechanisms. We also 
will discuss the more acute effects of steroids on behaviour, cognition 
and	 memory	 that	 act	 independently	 of	 sexually	 dimorphic	 mecha-
nisms, and may play major roles in the typical and atypical brain.
2.1 | Sexually dimorphic brain and behaviour 
mediated by testosterone- and oestrogen- induced 
nuclear receptor regulation
Transformative	 effects	 of	 steroids	 on	 sexual	 dimorphism	 of	 the	
brain first starts taking shape in humans during foetal development 
when there is a surge of testosterone in the male foetus during 8 to 
24 weeks of gestation,22,23 and this hormone surge is assumed to have 
long	lasting	structural	and	functional	effects	on	the	brain.	The	pres-
ence	of	 fetal	 testosterone	 (fT)	during	gestation	has	been	associated	
with greater grey matter volume in right temporoparietal junction/
posterior	superior	temporal	sulcus	(RTPJ/pSTS),	whereas	an	absence	
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of	fT	has	been	associated	with	greater	volume	in	planum	temporale/
planum	operculum	(PT/PO)	and	posterior	lateral	orbitofrontal	cortex	
(plOFC).23	Testosterone	exposure	during	the	prenatal	period	also	af-
fects	the	adult	sexually	dimorphic	nucleus	of	the	preoptic	area	(SDN-	
POA),	a	substructure	of	the	medial	preoptic	area	of	the	hypothalamus	
(MPOA)	in	humans,	which	is	2.2	times	larger	in	men	as	in	women.24	In	
rodent	studies,	the	spinal	cord	nucleus	(SNB;	spinal	nucleus	of	the	bul-
bocavernosus)	and	the	MPOA	and	especially	 its	substructure,	SDN-	
POA	are	also	larger	on	average	in	males	as	in	females,25,26 whereas, 
on	the	other	hand,	the	anteroventral	periventricular	nucleus	(AVPV)	is	
larger in females as in males.2
There	 is	a	hypothesised	role	of	 fT	 in	atypical	neurodevelopment	
through associative studies from our group which show significant as-
sociation	of	elevated	fT	levels	with	autism	when	compared	to	typical	
individuals,	and	fT	levels	were	positively	associated	with	higher	scores	
on	the	Childhood	Autism	Spectrum	Test	(CAST)	and	the	Child	Autism	
Spectrum	Quotient	 (AQ-	Child).27	 The	 brain	 region	 RTPJ,	which	 has	
been	shown	to	have	a	greater	volume	with	increased	fT,	is	also	known	
to be associated with autism.28,29	Additionally,	elevated	testosterone	
levels have been positively associated with occurrence of obsessive 
compulsive	disorder,	and	Tourette	syndrome,30 whereas elevated lev-
els of gestational oestrogens have been suggested to increase predis-
position to schizophrenia.31
The	mechanism	of	steroid-	induced	behavioural	outcomes	is	not	well	
understood, and why there is increased steroid hormone levels in indi-
viduals with neuropsychiatric conditions even less so. Research using 
animal	models	have	identified	two	major	pathways	for	 long-	term	sex	
steroid effects mediated by steroid receptors: apoptosis and epigenetic 
modulation.	Testosterone	 and	 oestrogens	 also	 induce	 acute	 changes	
to	 neuron	 and	 synapse	 structure	 through	 a	 protein	 kinase-	mediated	
mechanism,	 as	 discussed	 below.	 Sex-	specific	 behaviour	 is	 mediated	
through	nuclear	receptor	mechanisms	(Figure	1)	and,	according	to	the	
classical	model,	testosterone	and	androgen	receptor	(AR)	binding	has	
been	shown	 to	be	 responsible	 for	 sex-	specific	behavioural	effects	 in	
males.32,33	There	 is	additionally	a	parallel	mode	of	sexual	differentia-
tion	involving	oestrogens,	and	a	loss	of	both	oestrogen	receptors	(ERα 
and ERβ)	has	been	shown	to	cause	atypical	male-	specific	behaviour	in	
rats34 and, in males, ERα	is	thought	to	augment	male	sexual	behaviour,	
whereas ERβ	is	thought	to	supress	female	sexual	behaviour.35,36
2.1.1 | Programmed neuronal death
The	hormonal	control	of	cell	death	is	the	most	well-	established	mech-
anism	 associated	with	 sexual	 dimorphism	 of	 the	 brain.37	 Studies	 in	
rodent	models	have	 revealed	 sex-	specific	 activation	of	 apoptosis	 in	
particular subsets of neurons.34 Reduced neuronal death has been 
shown	to	be	responsible	for	larger	SNB	and	MPOA	in	males.25,26,38,39 
Neuronal death in these brain regions in females is ameliorated by 
treatment with oestrogens or testosterone,25,38 resulting in a perma-
nent	 reversal	and	masculinisation	 irrespective	of	biological	 sex.	 It	 is	
thought	that	aromatase	(CYP19),	which	is	responsible	for	the	synthe-
sis	of	oestrogens	from	testosterone	and	is	actively	expressed	in	brain	
regions	involved	in	sexual	differentiation,40,41 plays an important role 
in masculinisation, and the use of aromatase inhibitors has revealed re-
duced	male-	typical	sexual	behaviour	in	rats.	Interestingly,	it	has	been	
shown	that	apoptosis-	mediated	cell	death	is	not	responsible	for	sexual	
differences	in	the	ovine	SDN	(a	substructure	of	the	MPOA-	equivalent	
brain	region	in	sheep).42	The	sexually	dimorphic	brain	region	AVPV	is	
larger in females as a result of the unusual nature of oestrogen activ-
ity,	which,	 in	 the	male	AVPV,	 triggers	 apoptosis	 of	 neurons	 via	 the	
activity of both the ERα and ERβ.2,43,44
Mechanisms	 causing	 testosterone	 and	 oestrogen-	mediated	 sex-
ually	 dimorphic	 neuronal	 death	 include	 the	 modulation	 of	 Bcl-	2	
(anti-	apoptotic	factor)	and	Bax	(pro-	apoptotic	factor)	expression.45,46 
Oestrogens	increase	Bcl-	2	levels	and	decrease	Bax	levels	in	the	pre-	
optic area of rats,47 and testosterone is considered to have the same 
effect in an indirect fashion through aromatisation to oestrogens.
2.1.2 | Epigenetic mechanisms
A	 second	major	 cellular	 mechanism	 of	 steroid	 signalling	 involves	
epigenetic	modulation	to	bring	about	 long-	term	organisational	ef-
fects.	Testosterone	and	oestrogen	 signalling	 through	AR	and	ERs	
interact	 with	 histone-	modifying	 factors	 such	 as	 histone	 acetyl	
transferases to bring about profound gene regulatory effects.6,48,49 
ERα	 demonstrates	 high	 promoter	methylation	 in	 both	 sexes	 cor-
responding to reduced ERα	gene	expression	in	the	cortex,50,51 and 
a study using rats has shown that greater ERα promoter meth-
ylation is associated with higher neonatal maternal grooming and 
early	 oestradiol	 exposure.52	 Another	 study	 in	 mice	 showed	 that	
testosterone	administration	in	neonatal	females	altered	brain	DNA	
methylation	20-	fold	in	adulthood	to	shift	towards	a	male	methyla-
tion pattern,53	 whereas	 short-	term	 effects	 of	 testosterone	 were	
relatively	modest.	 This	 late-	emerging	 effect	 provides	 insight	 into	
the	vital	role	of	steroids	in	long-	term	sexually	dimorphic	molecular	
changes in the brain, and also shows the importance of the effect 
of	steroids	on	DNA	methylation	in	bringing	about	brain	sex-	specific	
organisation.
2.2 | Testosterone and oestrogens modulate 
immediate effects on cognition and memory by protein 
kinase pathways
2.2.1 | Behavioural effects
Testosterone	 and	 oestrogens	 are	 known	 to	 have	 long-	term	 effects	
on cortical organisation through mechanisms mediated by nuclear 
receptors. Current research has also uncovered the cytoplasmic 
mechanisms	of	action	and	localisation	of	AR	and	ERs	outside	the	cell	
nucleus, in membranes, dendritic spines and presynaptic terminals 
of neurons4,54	 (Figure	1),	 showing	more	 immediate	 kinase-	mediated	
effects54	on	behaviour	and	cognition	that	are	independent	of	sexual	
programming	during	development.	Immediate	effects	of	testosterone	
and oestrogens have been reported in human studies, such as in one 
study from our group where a single sublingual dose of testosterone 
administered to young women significantly impaired empathy and 
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social cognition,55 although the mechanism of action is not known. 
Another	study	reported	elevated	testosterone	levels	associated	with	
higher emotional arousal and amygdala activation in males.56	In	animal	
model studies, testosterone and oestrogen administration to ovariec-
tomised	adult	female	rats	appear	to	alter	sexually	dimorphic	behaviour	
in the radial maze and Morris water maze tasks,57-60 whereas oestro-
gen administration specifically appears to cause acute enhancement 
of memory consolidation with improvements in spatial and nonspatial 
memory tasks.61	As	 a	 result	of	 technical	 limitations	 associated	with	
working with human samples, cellular/molecular mechanisms in hu-
mans	are	poorly	understood,	although	some	steroid-	mediated	mecha-
nisms involving protein kinases have been identified in animal studies, 
as described below.
2.2.2 | Cellular/molecular mechanisms
General	 mechanisms	 responsible	 for	 testosterone	 and	 oestrogen-	
mediated learning and memory alterations involve structural and 
functional	 modulation	 of	 dendrites	 and	 dendritic	 spines.	 Animal	
studies have reported that the formation of new memories is as-
sociated with oestrogens, which increases dendritic spine density 
in	 the	CA1	 region	of	 the	hippocampus,	 at	 the	 same	 time	as	 caus-
ing	structural	changes	to	existing	spines.62 Dendritic spine density 
in	 the	 hippocampus	 CA1	 region	 has	 also	 been	 shown	 to	 increase	
upon	administration	of	testosterone,	and	this	process	is	oestrogen-	
independent.63,64 Previous studies from our group have also estab-
lished a role for oestrogens in the structural modulation of dendrites 
F IGURE  1 Nuclear	and	cytoplasmic	effects	of	steroid	hormones.	Schematic	diagram	describing	the	mechanism	of	actions	for	all	four	major	
classes	of	steroids.	Actions	are	classified	into	‘nuclear’	and	‘cytoplasmic’	(mediated	by	membrane-	bound	receptors)	and	further	described	
whether	such	actions	are	considered	to	be	beneficial	or	detrimental,	if	the	steroid	function	is	dysregulated.	The	nuclear	mechanism	of	steroid	
mediated	signalling	involves	binding	of	steroid	receptors	with	their	corresponding	steroid	receptor	element	(SRE).	Binding	to	androgen	and	
oestrogen	receptors	elements	(ARE	and	ERE)	have	been	associated	with	regulation	of	apoptotic	molecules,	Bax	and	Bcl2.	BAD,	Bcl2-	associated	
death	promoter;	CREB,	cAMP	response	element-	binding	protein;	GPER,	G-	protein	coupled	oestrogen	receptor;	GR,	glucocorticoid	receptor;	
JAK,	Janus	kinase;	MAPK,	mitogen-	activated	protein	kinase;	MPR,	mannose-	6-	phosphate	receptor;	PI3K,	phosphoinositide	3-	kinase;	PKA,	
protein	kinase	A;	STAT,	signal	transducer	and	activator	of	transcription
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in human neurons,18 and oestrogens have been shown not only to 
regulate synaptic transmission, but also to increase physical con-
nections between neurons.65 Dendritic spine density is regulated 
by	the	interaction	of	steroid	hormones	with	the	extracellular	signal	
regulated	kinase-	mitogen	activated	protein	(ERK-	MAP)	kinase	path-
way, and studies in mice have shown that inhibiting phosphoryla-
tion	of	ERK-	MAP	kinases	completely	prevents	oestrogen-	associated	
dendritic spine formation.5,65	 The	 effect	 of	 testosterone	 on	 spine	
density is mediated via the same mechanism, after conversion of 
testosterone into oestradiol intracellularly.66	 In	 addition	 to	 stimu-
lating	the	formation	of	nascent	excitatory	synapses,4,65 oestrogens 
also suppress signalling at inhibitory synapses.67,68	This	may	under-
lie	oestrogen’s	ability	to	influence	neuronal	excitability	and	seizure	
disorders.69	Oestrogens	are	also	known	to	induce	phosphoinositide	
kinase	and	protein		kinase	A	activity	through	the	G-protein	coupled	
oestrogen	 receptor	 (GPER),4,8	 Activation	 of	 GPER1	 in	 developing	
neurons	 results	 in	 the	 triggering	of	neurite	outgrowth	via	a	cAMP	
response	element-binding	protein-mediated	transcriptional	mecha-
nism.67,68	Interestingly,	activation	of	GPER	may	also	be	involved	in	
the	prevention	of	tau	protein	hyperphosphorylation	 in	Alzheimer’s	
disease,70,71	and	protect	against	glutamate	excitotoxicity	and	inhibi-
tion	of	GABA	neurotransmission.72–74 Moreover, signalling via GPER 
can also result in the rapid desensitisation of serotonin receptors 
to accelerate the selective serotonin reuptake inhibitor effect75,76 
and an increased signal transducer and activator of transcription 
 activation associated with the enhanced satiety response.77,78	Taken	
together,	the	rapid	protein	kinase-mediated	synaptic	effects	of	tes-
tosterone and oestrogens on cognition demonstrate a wider effect 
of steroid signalling in the brain not related to developmental pro-
gramming	or	sexual	differentiation.
2.3 | Additional transformative effect of 
progesterone and glucocorticoids through nuclear 
receptor- mediated mechanisms
2.3.1 | Progesterone
Neurodeteriorative effects
Progesterone, similar to oestrogens, has neuroprotective effects, and 
impacts	cognitive	 function	 (Figure	1).79	 In	some	cases,	progesterone	
has been shown to impair cognition and memory and, in other cases, 
it has been shown to demonstrate an enhancement.80	The	disruptive	
effect on memory and cognition is dependent on the timing of proges-
terone	administration.	For	example,	one	study	reported	an	 improve-
ment in working and spatial memory after ovariectomy in aged female 
rats, which was reversed on progesterone administration, demonstrat-
ing the detrimental effects of ovarian progesterone on the female 
brain.81	 Another	 study	 using	 human	 participants	 reported	 memory	
impairment and reduced response to faces in amygdala and fusiform 
gyrus after a single administration of progesterone.82	The	disruptive	
effect of progesterone is considered to occur through its metabolite 
allopregnanolone,	which	binds	to	GABAA receptors to produce an in-
hibitory	effect	and	alter	the	excitatory-	inhibitory	balance	in	the	central	
nervous	 system	 (CNS).83	The	disruptive	nature	of	allopregnanolone-	
GABAA receptor interaction also has therapeutic effects, as discussed 
later below.
Neuroenhancing effects
In	contrast	with	the	detrimental	effects	of	progesterone	described	
above, many studies have shown memory enhancement following 
progesterone	 administration.	One	 study	 reported	 prevention	 of	
age-	related	 memory	 loss	 in	 aged	 overiectomised	 rats	 following	
chronic administration of progesterone along with oestrogens.84 
In	 certain	 cases,	 the	 progesterone	 metabolite	 allopregnanolone	
is	 involved	 in	 the	 recovery	 of	 age-	related	 cognitive	 deficits.85 
Progesterone was also shown to enhance learning and memory, 
and	to	recover	age-	related	cognitive	decline	in	aged	wild-	type	as	
well as progesterone receptor knockout mice.86	A	possible	cellu-
lar mechanism for the role of progesterone as a memory enhancer 
is	 its	 ability	 to	 provide	 neuroprotection	 against	 oxidative	 stress	
in the hippocampus,87	by	down-	regulating	pro-	apoptotic	markers	
and	up-	regulating	anti-	apoptotic	markers.88	Some	studies	suggest	
that	 progesterone-	mediated	 neuroprotection	might	 be	 result	 of	
rapid	 membrane-	initiated	 kinase	 activity,	 which	 down-	regulates	
pro-	apoptotic	factors	such	as	Bcl2-	associated	death	promoter	and	
up-	regulates	anti-	apoptotic	factor	Bcl2,	and	this	pathway	is	trig-
gered via a membrane progesterone receptor.89-91	Although	 the	
effect	of	progesterone	on	the	brain	can	be	two-	pronged,	depend-
ing on the timing and dose of the hormone, in some conditions, 
controlled doses of progesterone has been beneficial in amelio-
rating neurological symptoms, as also  discussed later below.
2.3.2 | Glucocorticoids
Neurodeteriorative effects
Glucocorticoids	 (cortisol	 in	humans	and	corticosterone	 in	nonhu-
man	 mammals),	 similar	 to	 other	 steroid	 hormones,	 have	 an	 im-
portant	 function	 in	 the	 developing	 foetus,	 and	 are	 required	 for	
the	 normal	 growth	 and	 maturation	 of	 the	 cerebral	 cortex,	 the	
hippocampus and pituitary gland92	 (Figure	1).	 Studies	 in	 animal	
models	 have	 identified	 a	 high	 level	 of	 glucocorticoid-	mediated	
plasticity in the hippocampus including neurogenesis in dentate 
gyrus93 and structural modulation of dendrites and synapses in 
the	Ammon’s	 horn.94 However, similar to progesterone, the glu-
cocorticoid surge must occur at a precise developmental window 
and at a precise concentration to maintain normal developmental 
trajectories.95,96	 Studies	 have	 shown	 that	 glucocorticoid	 admin-
istration during late gestation can affect structural development 
of the foetal brain,97 including a reduced neuron density in the 
hippocampus.98	Antenatal	glucorticoid	administration	causes	thin-
ning	 of	 the	 anterior	 cingulate	 gyrus	 and	 exacerbates	 associated	
affective	 disorders	 such	 as	 anxiety	 and	 depression.	 Anomalous	
glucocorticoid	exposure	is	also	linked	with	an	increase	in	the	risk	
of cerebral palsy in preterm infants.99	Some	of	the	neurological	ef-
fects	of	early	glucocorticoid	exposure	also	appear	to	be	transmit-
ted across multiple generations.100	 In	humans,	persistent	 lifelong	
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modulation	of	 the	hypothalamic-	pituitary-	adrenal	 (HPA)	 axis	 can	
cause	 long-	term	fluctuations	of	blood	glucocorticoid	 level,	which	
can have adverse effects on psychiatric health.101	Glucocorticoid-	
induced stress can cause reduction in cognitive ability, including 
deteriorating	 working	 and	 nonverbal	 memory,	 mental	 flexibility	
and information processing.102	These	symptoms	have	been	associ-
ated with dendritic atrophy and synaptic loss in hippocampal neu-
rons.103 Glucocorticoids mediate cellular/molecular effects on the 
synapse and dendrites through both the glucocorticoid receptor 
(GR)	and	mineralocorticoid	receptor.104	The	promoter	region	of	GR	
is highly sensitive to stress and glucocorticoid administration, and 
one	study	has	reported	increased	histone	acetylation	and	DNA	de-
methylation associated with the GR promoter region when stress 
is low,105	 increasing	 GR	 expression,	 which	 is	 associated	with	 an	
increased	glucocorticoid-	induced	negative	feedback	loop	and	de-
creased	HPA	activity.106	Conversely,	increased	GR	promoter	DNA	
methylation has been associated with child abuse victims and peo-
ple who commit suicide.107
Neuroenhancing effects
The	effect	of	glucocorticoid-	mediated	stress	can	be	beneficial	when	
the	 individual	 is	exposed	to	 it	during	a	precise	window.108	For	ex-
ample, glucocorticoid administration just after a learning event fa-
cilitates	subsequent	consolidation	of	memory,	and	these	effects	are	
particularly	 strong	 for	 emotion-	related	memories.109-112 However, 
presentation of stress after memory retrieval affects reconsolidation, 
and later recall in the individual can be impaired.113-115	Additionally,	
exposure	 to	 stress	 before	 learning	 in	 some	 cases	 impairs	memory	
formation116,117 and, in other cases, enhances it.118,119 Low blood 
glucocorticoid levels have also been associated with enhanced cer-
ebral infusion, glucose utilisation and hippocampal neuron activity, 
which are reversed when glucocorticoid levels increase.120	This	es-
tablishes	 the	 complicated	 interaction	 of	 glucocorticoid-	mediated	
stress with cognition and memory, and the importance of admin-
istering a low concentrations of glucocorticoid at critical windows 
to have any beneficial effect on brain function. Further information 
on this topic is provided by Moisiadis and Matthews96	and	Sorrells	
et al.120
3  | STEROIDS AS THERAPEUTIC AGENTS
Of	the	wide-	ranging	functions	of	steroids,	oestrogens	and	progester-
one have consistently been shown to have a neurological ameliorative 
and enhancing role, and thus have been proposed as potential treat-
ments for certain neuropsychiatric and neurodegenerative conditions. 
Here, we discuss the ameliorative effects of oestrogens and proges-
terone, as well as their roles in the treatment of neuropsychiatric and 
neurodegenerative	conditions	(Table	1).
3.1 | Oestrogens
The	 cognitive	 enhancing	 effects	 of	 oestrogens,	 such	 as	 17β-	
oestradiol, have highlighted suggestions that oestrogens or 
oestrogen-	mimicking	compounds	may	be	a	useful	therapeutic	agent	
for neuropsychiatric conditions.11,14,121	 Studies	 in	 humans	 have	
shown a higher occurrence of schizophrenia in males, and increased 
psychosis in females during depletion of oestrogens,14,121 and the 
administration of 17β-	oestradiol	or	the	selective	oestrogen	receptor	
modulator,	 raloxifene,	has	demonstrated	a	positive	effect	on	well-
being and cognition for typical individuals, as well as for individuals 
with schizophrenia.122,123	The	mechanisms	by	which	17β-	oestradiol	
is beneficial in neuropsychiatric disorders are not well understood, 
although they are considered to occur partly through modulation 
of	mono-	amine	 production,	 including	 serotonin	 and	 dopamine,	 as	
well as through modulation of glutamatergic signalling, in addition 
to	anti-	inflammatory	effects.4,121	In	animals,	oestrogens	also	have	a	
mild	sexually	dimorphic	effect	on	a	traumatic	brain	injury	rat	model,	
with some studies showing higher survival in female rats,124,125 
whereas others report better neurological outcomes in males.126	In	
a rat model of spinal cord injury, oestrogen treatment can signifi-
cantly reduce apoptosis at the same time as enhancing the recovery 
of spinal cord functions.127
3.2 | Progesterone
Progesterone and its metabolite allopregnanolone have a neuropro-
tective function and are able to stimulate neurogenesis and enhance 
Steroid hormone Organism Therapeutic role
Oestrogen Human Wellbeing and improved cognition in typical and 
schizophrenic114,115
Rodents Higher survival of females after traumatic brain injury116,117
Positive neurological outcome in males118
Reduction of apoptosis and enhanced recovery after spinal 
cord injury119
Progesterone/
allopregnanolone
Human Protective	effect	in	Alzheimer’s	disease121
Rodents Reduced depression in Parkinson’s rat model122
Improved	hippocampal	structure	and	function	after	middle	
cerebral artery occlusion123
Reduced	cell	death	and	DNA	fragmentation	after	traumatic	
brain injury129
TABLE  1 Proposed therapeutic roles of 
oestrogens and progesterone
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cognition.128	 They	 have	 a	more	 predictable	 neuroprotective	 effect,	
which	is	not	sexually	dimorphic,	and	thus	have	been	more	extensively	
studied than oestrogens as a potential therapeutic agent for neu-
rodegenerative conditions. Progesterone has protective effects on 
human	neurodegenerative	conditions	such	as	Alzheimer’s	disease.129 
One	study	showed	that	 the	administration	of	progesterone	 to	a	 rat	
model	 of	 Parkinson’s	 disease	 significantly	 reduced	 depression-	like	
symptoms.130	Administration	of	progesterone	 and	 allopregnanolone	
to rats suffering from severe cerebral ischaemia after middle cerebral 
artery occlusion was found to improve the structure and function of 
the hippocampus, although the preservation of cognitive functions is 
significantly better if progesterone was administered before inducing 
cerebral ischaemia.131	 It	 is	 hypothesised	 that,	 even	 though	 there	 is	
severe neuronal loss in the hippocampus after ischaemia,132,133 the 
neuroprotective action of progesterone is able to enhance structure 
and plasticity of remaining neurons to condition them to carry out 
alternative strategies in the hippocampus or connected structures to 
restore some of the lost cognitive functions.134,135	Traumatic	injury	to	
the	rat	frontal	cortex	has	been	reported	to	kill	large	numbers	of	neu-
rons, as well as to produce acute inflammation, oedema, astrocyte hy-
pertrophy	and	blood-	brain	barrier	compromise,136 and progesterone 
and allopregnanolone have been used to alleviate its effects by reduc-
ing	cell	death	and	DNA	fragmentation,	as	well	as	protein	expression	
of	pro-	apoptotic	markers	caspase-	3	and	Bax,	in	addition	to	astrocyte	
hypertrophy.137	Allopregnanolone	has	also	been	successfully	used	to	
prevent neuronal death in animal models of stroke and spinal cord in-
jury,	and	this	involves	a	GABAA	receptor-	mediated	mechanism.
138-140 
The	benefits	can	be	usually	seen	after	only	a	brief	period	of	proges-
terone administration.
It	 is	 thus	evident	 that	both	oestrogens	and	progesterone	have	
neuroprotective effects on the brain and therefore may be useful 
for treating certain symptoms of brain injury, as well as neuropsy-
chiatric	 and	 neurodegenerative	 diseases.	The	 beneficial	 effects	 of	
oestrogens occur via the modulation of neurotransmitters such as 
serotonin, glutamate and dopamine in the brain, or by directly influ-
encing glutamatergic function. Progesterone and its metabolite allo-
pregnanolone appear to act by reducing apoptosis and a wide range 
of inflammation responses associated with brain injury, at the same 
time as structurally transforming hippocampal neurons to assist in 
the restoration of cognitive functions. However, one major limita-
tion of all these studies is that they have been mostly undertaken 
in animal models and how these data translate to humans remains 
unclear.	 Indeed,	 there	has	only	been	 limited	success	 in	 translating	
preclinical work into novel therapeutic agents to treat debilitating 
neurological, neurodevelopmental or neurodegenerative disorders. 
This	 lack	of	conversion	 is	a	result	of	many	factors,	although	these	
likely include species differences, as well as differences in brain 
complexity	and	disease-	specific	phenotypes.141	One	example	of	this	
has been the adoption of hormone therapy for neurological condi-
tions	 in	 humans.	 The	Women’s	 Health	 Initiative	 study	 reported	 a	
decrease in cognitive function and an increased risk of dementia 
and stroke in women over 65 years of age who received conjugated 
equine	oestrogens	plus	medroxyprogesterone	acetate	compared	to	
those who received placebo,142 despite an abundance of preclinical 
studies indicating a neuroprotective role for oestrogens in demen-
tia.	Although,	the	findings	of	these	studies	have	come	under	much	
criticism,143-146 it is nevertheless critical to develop a better under-
standing	of	how	potential	steroid-	based	therapeutic	agents	impact	
normal physiology in human neurons, as well as in appropriate mod-
els	of	disease	to	avoid	unwanted	side-	effects.	Although	the	use	of	
animal models is essential to such studies, the use of additional 
models that allow investigations in human neurons would be of huge 
benefit. Recent developments in human stem cell technologies es-
pecially	in	iPSC	technology,	have	enabled	researchers	to	model	the	
human brain in a Petri dish and, as this technology matures, there is 
the	potential	that	steroid	research	using	human-	derived	tissues	will	
accelerate the development of novel hormone therapies for neuro-
logical conditions.
4  | ROLE OF IPSCS IN NEUROSTEROID  
RESEARCH
4.1 | From iPSCs to specific neurons
The	 method	 of	 reprogramming	 adult	 somatic	 cells	 to	 pluripo-
tent	 stem	 cells	 was	 first	 described	 in	 2006	 by	 Takahashi	 and	
Yamanaka.147	 They	 reported	 that	 dermal	 fibroblasts	 from	 adult	
mice could be reprogrammed into a pluripotent state by retroviral 
transduction	of	four	transcription	factors:	OCT4,	KLF4,	c-	MYC	and	
SOX2.147	The	reprogrammed	cells	were	termed	iPSCs	and	these	are	
similar to embryonic stem cells in their morphology, proliferation, 
surface	antigens,	gene	expression	and	capacity	to	differentiate	into	
the	 cell	 types	 of	 the	 three	 primordial	 germ	 layers.	 Subsequently,	
Takahashi	et	al.148 applied the same technology to human adult der-
mal	 fibroblasts	 to	 generate	 the	 first	 human	 iPSCs.	 Following	 this	
discovery, other studies have shown that it is possible to generate 
human	iPSCs	from	other	adult	somatic	cell	types,	including	(but	not	
limited	 to)	 peripheral	 blood149 and hair follicles.150	Over	 the	 past	
10 years, an array of protocols has been developed that allow for 
the	differentiation	of	iPSCs	into	specific	neuronal	cell	types.	These	
protocols have taken advantage of a wealth of developmental stud-
ies that have detailed the steps and molecular cues involved in ani-
mal	embryology.	For	example,	the	first	step	in	the	development	of	
the neural tube, neural induction, is assumed to be the default path-
way	 involving	 the	bone	morphogenetic	proteins	 (BMPs),	Wnt	and	
fibroblast	 growth	 factor	 (FGF)	 signalling	 pathways.151-153 Neural 
induction leads to a default and primitive anterior identity, which 
is	 subsequently	patterned	by	extrinsic	morphogens	such	as	Wnts,	
FGFs,	 retinoic	 acid	 and	 Sonic	 Hedgehog,	 giving	 rise	 to	 forebrain,	
midbrain, hindbrain or spinal cord domains.
Neuronal	differentiation	of	iPSCs	follow	the	same	pathways	as	in	
vivo to give rise to mature neuronal populations.154	The	most	efficient	
neural	induction	of	human	iPSCs	is	achieved	by	dual	inhibition	of	the	
SMAD	signalling	pathway,	which	involves	the	synergistic	inhibition	of	
the	BMP	 and	 transforming	 growth	 factor-	β pathways to direct plu-
ripotent stem cells down a neuronal linage,152 ultimately giving rise 
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to a population of neural progenitors.152,154,155	These	neural	progen-
itor cells can then be patterned into neuronal cell types with regional 
identities using specific combinations of morphogens, small molecules, 
growth	factors	and	transcription	factors.	It	should	be	noted,	however,	
that	protocols	for	the	differentiation	of	iPSCs	into	neuronal	subtypes	
are imperfect, often yielding a heterogeneous population of cell types. 
Nevetheless, depending on the combination and timing of these 
signals, a variety of neuronal cell types can be obtained, including 
telecephalic precursors,156 midbrain dopaminergic neurons,157 basal 
forebrain cholinergic neurons158 and spinal motor neurons,159 as well 
as glial cells, such as astrocytes160 oligodendrocytes161	and	microglia-	
like cells.162
4.2 | IPSCs: the advantages and caveats of an  
in- vitro model of brain development
Much of the work aiming to identify cellular/molecular mechanisms 
of steroid action on the brain, cognition and memory has been car-
ried	out	using	animal	models.	Some	studies	have	manipulated	steroid	
hormones to investigate the effects on human behaviour; however 
there are very few studies that administered steroid hormones on in 
vitro	human	brain	 tissue	or	cells.	The	 limitations	of	animal	 research	
have resulted in the slow adoption of steroids as therapeutic agents. 
Advances	in	stem	cell	technologies	have	resulted	in	the	investigation	
of	steroid	hormone	interactions	in	a	human	system.	It	is	now	possible	
to	reprogram	human	somatic	cells	 into	iPSCs	to	study	the	closer	 in-
teraction of steroids with human target cells such as neurons derived 
from	 iPSCs.	This	approach	for	studying	the	nervous	system	has	the	
advantage	that	these	neurons	carry	the	same	genetic	make-	up	of	the	
donor.
The	rationale	 for	using	 iPSC-	derived	neuronal	 tissue	as	a	human	
system	to	expedite	clinical	 research	 is	very	strong.	The	human	brain	
develops	very	differently	from	the	rodent	brain	and	has	some	human-	
specific types of neurons not found in rodents.163-165 Moreover, some 
steroid molecules that are effective in humans are not as effective in 
rodents, whereas some steroid signalling mechanisms are also different 
in	humans	than	rodents.	For	example,	cortisol	is	the	active	glucocorti-
coid in humans, whereas corticosterone is more active in rodents.120 
It	is	also	not	clear	whether	the	aromatase	reaction	plays	an	important	
role in the developing human brain, and whether testosterone acts via 
its	native	receptor	AR	to	masculinise	the	brain	rather	than	being	con-
verted into oestrogens through the aromatase reaction, as observed 
in	animal	models.	 It	has	also	been	found	that,	 in	humans,	aromatase	
is	only	expressed	in	selective	brain	regions	such	as	the	preoptic	area,	
hypothalamus and amygdala.166,167 For these reasons, it is essential 
to	develop	in	vitro	human	iPSC	models	to	study	effects	of	steroids	in	
humans.	 It	 is	 also	possible	 to	accurately	 characterise	 the	 interaction	
of steroids with human gene products involved in synaptic and den-
dritic plasticity, and also to identify interactions with genes associated 
with neuropsychiatric conditions such as autism and schizophrenia. 
Additionally,	investigation	of	the	interactions	with	disease-	associated	
mutations will enable an understanding of how the cognition and mem-
ory enhancing effects of steroids can be better used as therapeutic 
agents	for	neurodegenerative	diseases	such	as	Alzheimer’s	disease	and	
Parkinson’s disease, neuropsychiatric conditions such as depression 
and schizophrenia, and traumatic cerebral and spinal injury.
However,	the	iPSC	method	is	not	without	its	issues.	Reprogramming	
of highly differentiated somatic cells such as skin cells or hair cells 
involves the interaction of key transcription factors with epigenetic 
molecules to transform the chromatin into an open state to promote 
higher active transcription.168-170 Most differentiated somatic cells 
have a closed chromatin state with several highly condensed heter-
ochromatin	regions	inhibiting	the	transcription	of	genes	not	required	
to maintain a somatic lineage.171 Unfortunately, the reprogramming 
method	is	highly	inefficient	and	not	completely	understood,	and	iPSCs	
can	 sometimes	 retain	 lineage-	specific	 chromatin	 signatures,	 thereby	
creating differentiation biases towards the original somatic cell.172 
There	are	also	issues	with	the	neuronal	differentiation	protocols.	The	
monolayer culture method, which is currently the most prevalent 
method	used	to	generate	iPSC-	neurons,	employs	a	dual	SMAD	inhi-
bition strategy to generate neurons,152,173 has several disadvantages. 
The	most	 important	one	 is	 it	 lacks	 spatial	organisation	of	 the	brain.	
Neuronal	morphology	and	gene	expression	is	also	heavily	dependent	
on the mechanical properties of cell adhesion to plate surface and 
neighbouring cells, whereas plating density and cell adhesion sub-
strate	determined	quantity	and	types	of	neurons.168
Thankfully,	 most	 of	 the	 issues	 are	 technical	 and	 some	 of	 them	
are	already	being	addressed.	For	example,	a	2017	study	showed	that	
histone H3K4 methylation patterns associated with somatic lineage 
identity are a major cause for the inefficiency of transcriptional re-
programming,174 suggesting that demethylation of methylated H3K4 
in	 iPSCs	might	 be	 a	 possible	 strategy	 for	 increasing	 reprogramming	
efficiency.	To	overcome	drawbacks	of	monolayer	cultures,	 there	has	
been rapid development of methods for generating cerebral organ-
oids,	which	 are	 able	 to	mimic	 the	 three-	dimensional	 (3D)	 structure,	
cell type composition and organisation, and connectivity of the human 
brain.175-177 Neurons in organoid cultures are able to demonstrate 
greater	 complexity	 of	 cellular	 interaction	when	 undergoing	 reduced	
stress	compared	to	monolayer	cultures.	Naturally	occurring	cell-	to-	cell	
contact seen in organoids also helps organise progenitors and neurons 
in layers typically observed in the human brain.168,175-177
4.3 | Studying the actions of steroids in human  
neurons
To	our	knowledge,	very	few	studies	have	directly	investigated	the	ac-
tions	of	steroids	in	human	neurons	generated	from	iPSCs.	The	cellular	
mechanisms associated with the clinical phenotypes are also not well 
understood,	especially	role	of	protein	kinase-	mediated	immediate	ef-
fects in humans. Moreover, there is little fundamental knowledge of 
the stoichiometric ratios of steroid biosynthesis pathway components 
in neuropsychiatric conditions, and very little understanding of why 
there is an elevated level of steroids associated with these conditions. 
Human	iPSC-	derived	neurons	provide	the	tools	to	carry	out	controlled	
experiments	aiming	to	 investigate	 these	previously	unidentified	cel-
lular/molecular mechanisms.
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Our	group	has	focused	on	the	generation	of	fore-	brain-	like,	glu-
tamatergic	neurons	from	iPSCs,	based	on	a	previously	described	pro-
tocol.154	We	first	generated	iPSCs	from	keratinocytes	in	hair	follicles	
using	a	non-	integrating	Sendai	virus	based	reprogramming	method	
(CytoTune-	iPS	Sendai	Reprogramming;	Thermo	Fisher	Scientific	Inc.,	
Waltham,	MA,	USA),	then,	using	the	aforementioned	neuron	differ-
entiation protocol, we generated mature and immature glutamater-
gic	neurons	within	40	days;	these	cells	express	a	range	of	proteins,	
including synaptic proteins associated with developing glutamater-
gic	neurons	(Figure	2A-	C).	Preliminary	data	demonstrated	that	male	
iPSC-	derived	 immature	 neurons	 respond	 to	 17β-	oestradiol	 expo-
sure.	 Specifically,	 17β-	oestradiol	 treatment	 for	 24	hours	 resulted	
in an increase in neurite outgrowth in these cells.18	 Interestingly,	
it was recently reported that 17β-	oestradiol	promoted	synapse	for-
mation	between	iPSCs-	derived	dopaminergic	neurons	and	HEK293	
cells and, furthermore, facilitated grafting of these neurons into stri-
atum of a rat model of Parkinson’s disease.178	Another	study	by	our	
group,	investigating	the	effect	of	testosterone	on	male	iPSC-	derived	
neurons	from	individuals	with	autism	using	a	real-	time	polymerase	
chain reaction,179	has	shown	elevated	differential	expression	of	AR	
in	autism	iPSC-	neurons	compared	to	control	iPSC-	derived	neurons,	
after just 24 hours of testosterone administration at physiological 
levels	 (2	nmol	L−1).180	Some	putative	downstream	genes	were	also	
differentially	 expressed	 on	 testosterone	 administration,	 such	 as	
brain-	derived	 neurotrophic	 factor,	 gonadotrophin-	releasing	 hor-
mone and apoptotic marker p38α	(Figure	2D).	This	suggested	differ-
ential	effect	of	testosterone	on	autism	 iPSC-	neurons	compared	to	
control neurons after only a short burst of hormone administration. 
Whether	 this	 is	 indicative	 of	 a	membrane-	mediated	 rapid	mecha-
nism of action for testosterone remains to be determined in future 
studies. Further studies will also be necessary to validate these ob-
servations, as well as the characterisation of phenotypic changes 
brought about by testosterone.
4.4 | Promise of organoids as a tool to study steroid 
hormone- brain interactions
Cerebral	organoids	are	self-	organised	brain	tissue	derived	from	stem	
cells,	generated	using	a	patterning	growth	factor-	free	culture	method	
to induce the transformation of embryoid bodies into neuroecto-
derm. By manipulating growth conditions and environment necessary 
for	mimicking	developmental	 cues,	 complex	brain	 tissue	 growth	 can	
be	 established	 exhibiting	 heterogeneous	 regionalisation	 of	 different	
brain	areas,	including	some	ventral	forebrain	regions,	dorsal	cortex	and	
choroid	 plexus.	Cerebral	 organoids	 also	 form	discrete	 cortical	 layers	
with	 stereotypical	 inside-	out	 organisation,	 as	well	 as	 human-	specific	
characteristics such as presence of outer radial glia and matured corti-
cal neurons with various pyramidal identities.176	This	 ability	of	 a	3D	
cerebral organoid culture to resemble the properties of the developing 
human brain more closely than monolayer cultures or animal models 
has made it a preferred model system for undertaking research into 
the human central nervous system, and it has been proposed to use 
this method to generate “personalised organoids” to test the effects 
of steroid hormones and develop drugs15,181,182	 (Figure	3).	 Steroid	
hormones with therapeutic properties such as oestrogens and proges-
terone	can	be	studied	by	generating	patient-	specific	organoids	in	3D-	
printed	mini-	bioreactors,	recently	developed	for	the	study	of	the	Zika	
virus on neurodevelopment.183 Human brain imaging and animal model 
studies have shown that testosterone and oestrogens have a well char-
acterised effect on cortical thickness,184-186 although the regulatory 
mechanisms are not known and the organoid system is perfectly suited 
for	this	kind	of	study.	Sexual	differentiation	of	cortical	microstructures	
can	also	be	studied	using	high-	throughput	organoid	cultures.
5  | CONCLUSIONS
We have reviewed the important role steroids play in development 
and	 sexual	 differentiation	 of	 the	 brain	 through	 a	 nuclear	 receptor	
mediated	mechanism.	 Sex-	dependent	 effects	 of	 steroids	 are	 long-	
term and involve the regulation of transcriptional and epigenetic 
machinery that brings about permanent changes to brain struc-
tures	 and	 functions.	 One	 well-	characterised	 mechanism	 of	 action	
is through differential modulation of apoptosis in neurons depend-
ing	on	biological	sex.	This	results	 in	 increased	size	of	brain	regions	
such	 as	MPOA	 and	 SNB	 in	 males,	 and	 a	 larger	 AVPV	 in	 females.	
The	acute,	 immediate	effects	of	steroids	on	cognition	and	memory	
are	evident	and	act	through	a	cytoplasmic	protein	kinase-	mediated	
mechanism.	 Testosterone	 and	 oestrogens	 are	 both	 able	 to	modu-
late dendritic spine density and structure, at the same time as al-
tering synaptic transmission, although they have different effects 
on	cognition.	Testosterone	 impairs	social	cognition,	and	 influences	
autistic traits, whereas oestrogens have neuroprotective effects and 
enhance memory consolidation and spatial and nonspatial memory 
tasks. Progesterone, similar to oestrogens, has neuroprotective ef-
fects on the brain, although this effect is highly dependent on the 
timing	 of	 exposure.	 The	 neuroprotective	 effect	 of	 progesterone	
against	oxidative	stress	in	the	hippocampus	has	a	memory	enhanc-
ing	effect,	whereas	its	metabolite,	allopregnanolone	binds	to	GABAA 
receptors	 increasing	 inhibition	of	 the	CNS	and	 thus	disrupting	 the	
excitatory-	inhibitory	 balance.	 Glucocorticoids,	 the	 primary	 stress	
hormone,	have	similar	time-	dependent	and	dose-	dependent	effects	
on	the	brain.	Although	high	doses	of	glucocorticoids	are	harmful	to	
the	brain,	low	levels	of	glucocorticoid	exposure	during	specific	peri-
ods of the learning process can significantly enhance memory con-
solidation, especially if they are related to emotions.
Because steroids and their metabolites have been recurrently pro-
posed as potential therapeutic avenues for a range of neurodevelop-
mental, neuropsychiatric and neurodegenerative disorders, there is a 
compelling to supplement and future preclinical studies carried out in 
animal models, with those carried out in human neurons. However, 
because	many	of	 these	disorders	have	complex	aetiologies	and	un-
derlying molecular and genetic underpinnings, it is not always pos-
sible	 to	 recapitulate	 this	 in	 animal	models.	Therefore,	 translating	or	
refining such findings from preclinical studies into therapies is not 
straightforward.	 Deriving	 iPSCs	 from	 specific	 patient	 cohorts	 with	
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F IGURE  2 Understanding	the	effects	of	testosterone	using	induced	pluripotent	stem	cell	(iPSC)-	neurons	derived	from	typically	or	atypically-	
developing	individuals.	(A-	C)	Example	of	day	45	human	iPSC-	neurons	expressing	key	neuronal	and	synaptic	proteins	(scale	bar=10	μm).	After	
45	days,	iPSC-	neurons	are	positive	for	the	microtubule-	associated	protein,	MAP2	(green)	(A),	the	pre-	synaptic	protein,	Synapsin-	1	(B)	and	
the	post-	synaptic	protein	Ca2+/calmodulin-	dependent	protein	kinase	II	(CaMKII)	(C).	(D)	Preliminary	data	of	the	effects	of	testosterone	(T)	
treatment	(24	h)	on	differential	gene	expression	(log-	fold	change,	P≤.05)	of	androgen	receptor	(AR),	brain-derived	neurotrophic	factor	(BDNF),	
gonadotrophin-	releasing	hormone	(GnRH)	and	p38a.	iPSC	lines	were	generated	from	typically	developed	individuals	(control:	CTR.M3)	or	
atypically	developing	individuals	(ie,	patient	diagnosed	with	autism-	spectrum	disorder	[ASD.M1]).	DAPI,	4’,6-	diamidino-	2-	phenylindole.	Error	
bars	indicate	the	SEM
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similar genetic background and clinical phenotyping, has the potential 
to improve our understanding of how steroid- based therapies can be 
used and, more importantly, possibly improved. Recent developments 
in	 iPSC	technologies,	along	with	the	ability	 to	recapitulate	develop-
ing 3D brain structures of individual donors, has made it possible to 
undertake	 high-	throughput	 testing	 of	 steroid	 molecules,	 including	
several recently discovered neurosteroids that endogenously medi-
ate neuronal functions previously not known to be associated with 
steroid signalling pathways. Future studies into the synthesis and 
mechanisms of action of these neurosteroids will further enhance our 
understanding of the effects of steroids on the brain, and enable us 
to isolate compounds with greater therapeutic potential for neurode-
generative conditions.
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